Common Contracts
2 similar Agreement contracts by Finch Therapeutics Group, Inc.
FINCH THERAPEUTICS, INC. AND MILLENNIUM PHARMACEUTICALS, INC. AMENDED AND RESTATED AGREEMENTAgreement • February 26th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Agreement (“Agreement”) is entered into as of October 21, 2019 (“Restatement Effective Date”) by and between Finch Therapeutics, Inc., a Delaware corporation having its principal office at 200 Inner Belt Road, 4th Floor, Somerville, Massachusetts 02143 (“Finch”), and Millennium Pharmaceuticals, Inc., a Delaware corporation having its principal office at 40 Landsdowne Street, Cambridge, Massachusetts 02139, USA (“Takeda”), an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, and sets forth the terms and conditions that will apply to the performance of certain research and development work by each party and the grant by Finch to Takeda of certain licenses to proprietary Finch technology.
FINCH THERAPEUTICS, INC. AND MILLENNIUM PHARMACEUTICALS, INC. AMENDED AND RESTATED AGREEMENTAgreement • February 9th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Agreement (“Agreement”) is entered into as of October 21, 2019 (“Restatement Effective Date”) by and between Finch Therapeutics, Inc., a Delaware corporation having its principal office at 200 Inner Belt Road, 4th Floor, Somerville, Massachusetts 02143 (“Finch”), and Millennium Pharmaceuticals, Inc., a Delaware corporation having its principal office at 40 Landsdowne Street, Cambridge, Massachusetts 02139, USA (“Takeda”), an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, and sets forth the terms and conditions that will apply to the performance of certain research and development work by each party and the grant by Finch to Takeda of certain licenses to proprietary Finch technology.
